XSpray Pharma (Sweden) Investor Sentiment

XSPRAY Stock  SEK 29.25  5.30  15.34%   
About 60% of XSpray Pharma's investor base is looking to short. The analysis of current outlook of investing in XSpray Pharma AB suggests that many traders are alarmed regarding XSpray Pharma's prospects. The current market sentiment, together with XSpray Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use XSpray Pharma AB stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at news.google.com         
Interim Report Second Quarter 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
New number of shares and votes in Xspray Pharma - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
U.s. SP 500 E-Mini Futures Up 0.13, Nasdaq Futures Up 0.19 ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Xspray Pharma receives request for additional information concerning Dasynoc from FDA - Marketscreen...
Google News at Macroaxis
over a year ago at news.google.com         
Adocia, plus forte hausse du march SRD la clture du jeudi 6 ... - Zonebourse.com
Google News at Macroaxis
over a year ago at news.google.com         
Baker McKenzie legal advisor to Pareto Securities and Zonda ... - Baker McKenzie
Google News at Macroaxis
over a year ago at news.google.com         
Xspray Pharma AB Are Analysts Optimistic - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Xspray raises approximately SEK 251 million through a rights issue - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Understanding Fiduciary Duties and Obligations in Investment and ... - JD Supra
Google News at Macroaxis
over a year ago at news.google.com         
Xspray has published prospectus relating to its previously announced rights issue - Marketscreener.c...
Google News at Macroaxis
over a year ago at news.google.com         
The Board of Directors of Xspray has resolved on a previously announced rights issue of units of app...
Google News at Macroaxis
over a year ago at news.google.com         
Bulletin from the extraordinary general meeting of Xspray Pharma AB - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Bulletin from the 2023 annual general meeting of Xspray Pharma AB - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Xspray Pharma Q1 2023 - First quarter of a transformative year ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product l...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about XSpray Pharma that are available to investors today. That information is available publicly through XSpray media outlets and privately through word of mouth or via XSpray internal channels. However, regardless of the origin, that massive amount of XSpray data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of XSpray Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of XSpray Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to XSpray Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive XSpray Pharma alpha.

XSpray Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for XSpray Stock analysis

When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities